Company Description
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases.
Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis.
Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial.
Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 180 |
| CEO | Joseph Payne |
Contact Details
Address: 10628 Science Center Drive, Suite 250 San Diego, California 92121 United States | |
| Phone | 858 900 2660 |
| Website | arcturusrx.com |
Stock Details
| Ticker Symbol | ARCT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001566049 |
| CUSIP Number | 03969T109 |
| ISIN Number | US03969T1097 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph E. Payne M.Sc. | Founder, President, Chief Executive Officer and Director |
| Dr. Padmanabh Chivukula Ph.D. | Founder, Chief Scientific Officer, Chief Operating Officer and Secretary |
| Andrew H. Sassine MBA | Chief Financial Officer and Director |
| Lance Kurata | Chief Legal Officer |
| Neda Safarzadeh | Vice President and Head of IR/PR and Marketing |
| Natash O. Bowman | Chief Human Resources Officer |
| Kevin T. Skol | Chief Business Officer |
| Dr. Juergen Froehlich FCPh, M.D., MBA | Chief Medical Officer |
| Dr. Igor Smolenov M.D., Ph.D. | Chief Development Officer |
| Roberta Duncan | Chief Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 10, 2024 | CT ORDER | Filing |
| Feb 14, 2020 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 1, 2019 | 8-K | Current Report |
| Jun 21, 2019 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 20, 2019 | 8-K | Current Report |
| May 20, 2019 | 8-K | Current Report |
| May 13, 2019 | 8-K | Current Report |
| May 13, 2019 | 10-Q | Quarterly Report |
| Apr 12, 2019 | EFFECT | Notice of Effectiveness |
| Apr 12, 2019 | 424B3 | Prospectus |